Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.

AIM To investigate the prognostic significance of phosphatase regenerating liver 3 (PRL-3) protein expression in gastric cancer. METHODS PRL-3 expression in paraffin-embedded tumor specimens from 293 patients with gastric cancer was studied retrospectively by immunohistochemistry. Monoclonal antibody specifically against PRL-3, 3B6, was obtained with hybridoma technique. RESULTS Positive PRL-3 expression was detected in 43.3% (127 of 293) of gastric cancer cases. High expression of PRL-3 was positively correlated with tumor size, depth of invasion, vascular/lymphatic invasion, lymph node metastasis, high TNM stage and tumor recurrence. Patients with positive PRL-3 expression had a significantly lower 5-year survival rate than those with negative expression (28.3% vs 51.9%, P < 0.0001). Patients who received curative surgery, and with positive PRL-3 expression had a significant shorter overall survival and disease-free disadvantage over patients with negative expression (hazard ratio of 16.7 and 16.6, respectively; P < 0.0001 for both). Multivariate analysis revealed that PRL-3 expression was an independent prognostic indicator for overall and disease-free survival of gastric cancer patients, particularly for survival in TNM stage III patients. CONCLUSION PRL-3 expression is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection.

[1]  Henry Z. Montes,et al.  TNM Classification of Malignant Tumors, 7th edition , 2010 .

[2]  G. Capellá,et al.  PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness , 2008, British Journal of Cancer.

[3]  S. Cai,et al.  Expression and prognostic impact of PRL‐3 in lymph node metastasis of gastric cancer: Its molecular mechanism was investigated using artificial microRNA interference , 2008, International journal of cancer.

[4]  Q. Zeng,et al.  Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice , 2008, Cancer biology & therapy.

[5]  S. Cai,et al.  Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis , 2007, Surgery Today.

[6]  G. Sandusky,et al.  Cellular Localization of PRL-1 and PRL-2 Gene Expression in Normal Adult Human Tissues , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[7]  Q. Zeng,et al.  PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. , 2006, Cancer research.

[8]  B. Dong,et al.  Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Cai,et al.  Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. , 2006, Biochemical and biophysical research communications.

[10]  L. Kiesel,et al.  Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer , 2006, British Journal of Cancer.

[11]  C. Shou,et al.  Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3. , 2006, Biochemical and biophysical research communications.

[12]  A. Cox,et al.  PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. , 2006, Cancer research.

[13]  D. V. Von Hoff,et al.  PRL phosphatases as potential molecular targets in cancer , 2005, Molecular Cancer Therapeutics.

[14]  Q. Zeng,et al.  Generation of PRL-3- and PRL-1-Specific Monoclonal Antibodies as Potential Diagnostic Markers for Cancer Metastases , 2005, Clinical Cancer Research.

[15]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[16]  K. Klinger,et al.  Alterations in Vascular Gene Expression in Invasive Breast Carcinoma , 2004, Cancer Research.

[17]  M. Kasuga,et al.  High Expression of PRL-3 Promotes Cancer Cell Motility and Liver Metastasis in Human Colorectal Cancer , 2004, Clinical Cancer Research.

[18]  J. Li,et al.  Catalytic domain of PRL-3 plays an essential role in tumor metastasis: Formation of PRL-3 tumors inside the blood vessels , 2004, Cancer biology & therapy.

[19]  A. Bardelli,et al.  PRL-3: A phosphatase for metastasis? , 2004, Cancer biology & therapy.

[20]  S. Semba,et al.  Expression of PRL-3 Phosphatase in Human Gastric Carcinomas: Close Correlation with Invasion and Metastasis , 2004, Pathobiology.

[21]  Weontae Lee,et al.  Structure of human PRL‐3, the phosphatase associated with cancer metastasis , 2004, FEBS letters.

[22]  C. Shou,et al.  The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[23]  G. Kozlov,et al.  Structural Insights into Molecular Function of the Metastasis-associated Phosphatase PRL-3* , 2004, Journal of Biological Chemistry.

[24]  C. Shou,et al.  Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3. , 2004, Hybridoma and hybridomics.

[25]  Saïd M. Sebti,et al.  Searching for the elusive targets of farnesyltransferase inhibitors , 2003, Nature Reviews Cancer.

[26]  K. Kinzler,et al.  PRL-3 expression in metastatic cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Li,et al.  PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. , 2003, Cancer research.

[28]  E. Borden,et al.  Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. , 2002, Molecular cancer therapeutics.

[29]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[30]  Klemens Rottner,et al.  The lamellipodium: where motility begins. , 2002, Trends in cell biology.

[31]  J. Waxman,et al.  Analysis of stromal-epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene. , 2002, Cancer letters.

[32]  Michael A. Choti,et al.  A Phosphatase Associated with Metastasis of Colorectal Cancer , 2001, Science.

[33]  J. Dixon,et al.  Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. , 2001, Biochemical and biophysical research communications.

[34]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[35]  H. Horstmann,et al.  Prenylation-dependent Association of Protein-tyrosine Phosphatases PRL-1, -2, and -3 with the Plasma Membrane and the Early Endosome* , 2000, The Journal of Biological Chemistry.

[36]  Alan Hall,et al.  Rho GTPases Control Polarity, Protrusion, and Adhesion during Cell Movement , 1999, The Journal of cell biology.

[37]  Y. Tan,et al.  Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. , 1998, Biochemical and biophysical research communications.

[38]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[39]  D. Crowell,et al.  Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. , 1996, Cancer letters.

[40]  Y. Maehara,et al.  Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. , 1996, Surgery.

[41]  R. Taub,et al.  PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth , 1994, Molecular and cellular biology.

[42]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[43]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.